Progressive Insider Sold Shares Worth $2,680,900, According to a Recent SEC Filing-July 2024-www.financetom.com

Progressive Insider Sold Shares Worth $2,680,900, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Progressive Insider Sold Shares Worth $2,680,900, According to a Recent SEC Filing

Dec 3, 2024 8:57 AM

11:32 AM EST, 12/03/2024 (MT Newswires) -- John P Sauerland, Vice President and Chief Financial Officer, on November 29, 2024, sold 10,000 shares in Progressive (PGR) for $2,680,900. Following the Form 4 filing with the SEC, Sauerland has control over a total of 306,280 shares of the company, with 292,958 shares held directly and 13,322 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/80661/000112760224028367/xslF345X05/form4.xml

Price: 263.74, Change: -0.30, Percent Change: -0.11

Previous page： Natixis and Generali in early talks for asset management tie-up, FT reports Next page： Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Natixis and Generali in early talks for asset management tie-up, FT reports

Nov 25, 2024

Nov 25 (Reuters) - France's Natixis Investment Managers is holding early-stage talks with Italian insurer Generali about a potential tie-up, the Financial Times reported on Monday. The firms have not yet agreed to terms of a deal, and it remains uncertain whether the talks will lead to an agreement, the report added, citing sources. A spokesperson for BPCE, the parent...

Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies

Nov 25, 2024

Cassava Sciences Inc. stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease. The trial did not meet the pre-specified co-primary, secondary, and exploratory biomarker endpoints. In July, CEO Rick Barry wrote a letter to shareholders and employees, saying that the company is in the final stages of testing simufilam...

KULR Gets US Navy Contract to Develop Technology for Battery Safety

Nov 25, 2024

09:28 AM EST, 11/25/2024 (MT Newswires) -- KULR Technology ( KULR ) said Monday it has been awarded a contract by the US Navy to develop high-temperature internal short circuit cells for improved battery safety in critical applications. The project will support a wide range of uses, particularly in the aviation sector, by allowing the simulation of extreme conditions to...

MicroStrategy Provides Update on Bitcoin Holdings

Nov 25, 2024

09:21 AM EST, 11/25/2024 (MT Newswires) -- MicroStrategy ( MSTR ) said Monday that it purchased 55,500 bitcoins for $5.4 billion in cash, at an average price of $97,862 per bitcoin between Nov. 18 and Nov. 24. As of Nov. 24, MicroStrategy ( MSTR ) owned 386,700 bitcoins, with a total purchase price of $21.9 billion and an average price...